{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.0","upperLimit":"71.2","value":"63.7"},{"groupId":"OG001","lowerLimit":"41.7","upperLimit":"58.4","value":"50.4"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.8","upperLimit":"50.4","value":"42.2"},{"groupId":"OG001","lowerLimit":"17.3","upperLimit":"31.5","value":"24.1"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.8","upperLimit":"35.9","value":"28.1"},{"groupId":"OG001","lowerLimit":"7.6","upperLimit":"18.5","value":"12.4"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.3","upperLimit":"30.3","value":"23.0"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"13.3","value":"8.0"}]}],"title":"24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"22.2","value":"15.6"},{"groupId":"OG001","lowerLimit":"2.7","upperLimit":"10.6","value":"5.8"}]}],"title":"36 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"19.5","value":"13.1"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"8.8","value":"4.4"}]}],"title":"48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.4","upperLimit":"18.5","value":"12.3"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"7.8","value":"3.6"}]}],"title":"60 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"17.5","value":"11.4"},{"groupId":"OG001","lowerLimit":"0.8","upperLimit":"6.7","value":"2.7"}]}],"title":"72 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"15.5","value":"9.6"},{"comment":"Lower and upper limit not calculated due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0.0"}]}],"title":"84 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"The overall survival rate is the probability that a participant will be alive at the specified timepoints following randomization. Overall survival was defined as the time between the date of randomization and the date of death as a result of any cause. Survival rates were determined via Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.","id":"OG001","title":"Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to the specified timepoints, up to 84 months","title":"Overall Survival (OS) Rate in All Randomized Participants - Extended Collection","type":"POST_HOC","unitOfMeasure":"Percent probability of OS"}